CEO’s Corner

Spring 2024

We recently had the pleasure of participating in the 2024 Global Health Summit campaign with a short documentary about shaping progress in the slow-changing industry of drug development. The Global Health Summit centers on organizations coming together to explore pioneering developments within the healthcare sector to drive innovative solutions to pressing global health issues. And I was honored that Altasciences was asked to participate in this year’s campaign. 

I was joined by my colleagues Steve Mason (Co-COO), Marie-Hélène Raigneau (Co-COO), and Dr. Gaetano Morelli (Chief Medical Officer) to discuss the inefficiencies and obstacles clients face with the traditional outsourcing paradigm. We also spoke about how Altasciences has broken from tradition to offer an alternative path for clients, to help them bring better drugs to people in need all over the world—and to help them do it faster, without compromising quality or safety. Contributing to that progress and mission is a daily priority I hold close to my heart.

The release of this video was a great reminder of all the incredible progress our team has already contributed to drug development. When you select Altasciences as your drug development partner, know that we take the utmost pride in helping you move your molecules from preclinical to Phase I, Phase II, and beyond.

To that end, here are just a few of the many of programs that recently came through Altasciences, and I want to share some of the ways we have worked together with our clients to change the lives of patients worldwide. 

• We helped a biopharmaceutical company dedicated to developing mental health therapies complete the necessary work to advance into human trials.
• We supported another pharmaceutical company’s psychedelic drug by moving it rapidly through early development with our preclinical, clinical, and bioanalytical work. 
• We helped a client make significant progress to deliver the first treatment for a serious brain disorder with unmet needs. 
• We fast tracked clinical trials of a novel gene therapy.
• We dosed the first patient on a first-in-human trial studying a medication for a neuromuscular disease.
• We helped a client address the devastating impacts of the opioid crisis and addiction. 
• Our clinical team provided key early human-safety data for a client’s treatment of a rare heart arrhythmia. 
• We supported a client in optimizing a treatment for rare pediatric disorders.
• We kicked off clinical trials for a client’s new treatment for cognitive impairment.

Thank you for entrusting Altasciences with your molecules. We are humbled to be part of your efforts in shaping progress and supporting health.

Until next time,